Therapeutic advances for glioblastoma multiforme: Current status and future prospects

被引：45
作者：
Robins H.I. [1 ]
Chang S. [1 ]
Butowski N. [1 ]
Mehta M. [1 ]
机构：
[1] University of Wisconsin Comprehensive Cancer Center, Madison
来源：
Current Oncology Reports | 2007年 / 9卷 / 1期
关键词：
North American Brain Tumor Consortium; Rain Tumor; Meaningful Advancement; Common Central Nervous System Malignancy;
D O I：
10.1007/BF02951428
中图分类号：
学科分类号：
摘要：
Glioblastoma multiforme (GBM) is the most common central nervous system malignancy. It is rapidly progressive with rare opportunity for cure. After three-decades of laboratory and clinical research;: a newly evolved chemoradiotherpy approach using the alkylating agent temozolomide during and after radiotherapy has resulted in the first significant impact on this disease. Here we, discuss the basis for this positive interaction as well as potential mechanisms of resistance to it. Additionally, in the context of current and planned research, we explore approaches to take advantage of this combination and the use of targeted therapies to exploit cell signaling alterations found in GBM. We anticipate that a multimodality approach directed at tumor-specific biology will result in more meaningful advancements in the treatment of this fatal disease. Copyright © 2007 by Current Medicine Group LLC.
引用
收藏
页码：66 / 70
页数：4
相关论文
共 34 条
[1]  
Grossman S.A., Batara J.F., Current management of glioblastoma multiforme, Semin Oncol, 31, pp. 635-644, (2004)
[2]  
Stupp R., Mason W.P., van den Bent M.J., Et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, 352, pp. 987-996, (2005)
[3]  
Walker M.D., Alexander Jr. E., Hunt W.E., Et al., Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial, J Neurosurg, 49, pp. 333-343, (1978)
[4]  
Fine H.A., Dear K.B., Loeffler J.S., Et al., Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults, Cancer, 71, pp. 2585-2597, (1993)
[5]  
Stewart L.A., Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials, Lancet, 359, pp. 1011-1018, (2002)
[6]  
Gilbert M.R., Friedman H.S., Kuttesch J.F., Et al., A phase U study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy, Neurooncology, 4, pp. 261-267, (2002)
[7]  
Westphal M., Hilt D.C., Bortey E., Et al., A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma, Neurooncology, 5, pp. 79-88, (2003)
[8]  
Stupp R., Dietrich P.Y., Ostermann Kralievic S., Et al., Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide, J Clin Oncol, 20, pp. 1375-1382, (2002)
[9]  
Tolcher A.W., Gerson S.L., Denis L., Et al., Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules, BrJ Cancer, 88, pp. 1004-1011, (2003)
[10]  
Hegi M.E., Diserens A.C., Gorlia T., Et al., MGMT gene silencing and benefit from temozolomide in glioblastoma, N Engl Med, 352, pp. 997-1003, (2005)
1234